about
Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligoJean-Claude Bystryn 1938-2010. An obituary.The transcription factors SOX9 and SOX10 are vitiligo autoantigens in autoimmune polyendocrine syndrome type I.The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo.Management of vitiligo.Autoimmune melanocyte destruction in vitiligo.Serial studies of autologous antibody reactivity to melanoma. Relationship to clinical course and circulating immune complexes.GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1.Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.GILT modulates CD4+ T-cell tolerance to the melanocyte differentiation antigen tyrosinase-related protein 1.Mammalian tyrosinase-related protein-1 is recognized by autoantibodies from vitiliginous Smyth chickens. An avian model for human vitiligoOcular pathology in melanomatous Sinclair miniature swine.Autoantibodies as diagnostic and predictive markers of vitiligo.Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus proteinSelf antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapyCellular stress and innate inflammation in organ-specific autoimmunity: lessons learned from vitiligo.Update on the genetics characterization of vitiligo.Vitiligo: auto-immunity and immune responses.Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality?Altered expression of four miRNA (miR-1238-3p, miR-202-3p, miR-630 and miR-766-3p) and their potential targets in peripheral blood from vitiligo patients.Alopecia totalis and vitiligo in common variable immunodeficiencyInteractome analysis of gene expression profile reveals potential novel key transcriptional regulators of skin pathology in vitiligo.Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8.Organ-specific autoimmunity: a 1986 overview.Patients affected by vitiligo and autoimmune diseases do not show antibodies interfering with the activity of the melanocortin 1 receptor.Function-blocking autoantibodies to the melanin-concentrating hormone receptor in vitiligo patients.Melanocyte destruction and repopulation in vitiligo.Review of the etiopathomechanism of vitiligo: a convergence theory.Vitiligo: where do we stand?Recognition of autoantigens by patients with melanoma.High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo.Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer.Genetic variations in nalp1 mRNA expressions in human vitiligo.Ocular pathology in the minimally depigmented subline of the vitiliginous Smyth chicken.Morphology of melanocytes in hair bulbs and eyes of vitiligo mice.Treatment of vitiligo vulgaris with the combination therapy of topical steroid and vitamin D3 compound.Vitiligo: peripheral T-cell subset imbalance as defined by monoclonal antibodies.Depletion and repopulation of Langerhans cells in nonsegmental type vitiligo.Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1.Vitiligo: the historical curse of depigmentation.
P2860
Q24794301-14834C31-7573-446A-9BFB-F604CEF0B916Q30399726-A14A1B2C-1E71-4D5E-9092-C39F85BA120AQ30681365-28525846-DDFD-4EF5-BF63-1CF251EBD25AQ30829628-15C640ED-3643-4B73-A2C3-3AB3D2488F68Q34135395-0170E36E-A3E7-4ADB-BDCE-3EFD557B30CAQ34335855-4FDDD081-7F15-4EB6-8C63-71CCCDE80DD9Q34550480-E67A2A9B-49A4-482F-B738-5C97D12214A8Q34692289-E75022FF-5E18-4E0C-B292-5173B4890A3DQ35064131-F7AEE7E5-9881-4BFF-816A-BD58D46FA109Q35552274-4ECB0B80-E3C5-452E-946F-8C99C05F55D1Q35798261-78564B91-D300-4951-ABA5-FF40898809FCQ35818436-0031A81E-858A-4127-8795-1D6167FAB388Q35934690-D7AC0E1F-A97C-4DED-B5D9-57AA10F3F234Q36365511-D6159FB6-1925-40C2-AF2C-D05C0DEC54E1Q36380506-B09FEAB7-3F91-4DC7-ABA0-2C01BCF213D7Q36389114-D1DF0A11-A5FA-4387-88BB-A6D46F93E18BQ36465456-840D14A4-364A-44A5-A6AE-EF88A8D50501Q36478782-14010176-C367-4157-BC4C-0D5871DA80B5Q36958358-C9ABCAA1-40C0-411C-9E58-AE51AF83FEDDQ38433669-8D7ED215-9E54-4E45-AC63-EE723A0B69FAQ38651121-D155C3C4-E5A8-4E6D-A784-F51E36268E40Q38943432-A7E3C5BF-5271-4D72-AAF1-7E80F3C57ADEQ39331724-B3E56714-3E80-43E3-8DD7-C31F5FC63868Q39506816-F010679B-325F-4C8D-9F07-828F84640E69Q39723783-3AD9154C-980D-4BCE-B3C6-4CB66AACF788Q40282263-BD0A01C6-4548-4C5B-BABD-5974655274ECQ40591940-ECEE14FE-FA3C-4C3F-8CAA-0B3D4DCB3287Q40742658-A010C92A-6038-4FA6-8FB2-3A345A8A54C8Q40820967-884E4C3B-F31F-45D6-9102-59B85673C0ACQ40844530-20EF6570-C4BA-42A5-909D-E13EB8B6074CQ41007804-DF4B844B-6BEA-4A79-8957-0D5130281348Q41932115-840FAE7E-E5C8-44CC-AE66-91B4501913BAQ42110711-E9F00069-C13B-4CC9-B82D-1A74D3F5ED97Q42513433-BBBC09D5-6C19-4F7F-A65C-E3C99A3483A6Q42738212-35F3897D-E9BC-49AE-AD07-43163A19DFC5Q42966362-6D186707-9D0B-4EC1-B354-DD895F76C572Q43916658-DB34BF3B-DC3F-4420-9B27-F0AF283EB04CQ44113239-9EB32B27-86F9-4D58-A118-5BFC81E73395Q44116002-3B61171D-650C-4312-94A1-EBDEDC623B9AQ47286652-5E1357E2-E4D0-4CB0-95E1-82C1126DA4EE
P2860
description
1983 nî lūn-bûn
@nan
1983年の論文
@ja
1983年論文
@yue
1983年論文
@zh-hant
1983年論文
@zh-hk
1983年論文
@zh-mo
1983年論文
@zh-tw
1983年论文
@wuu
1983年论文
@zh
1983年论文
@zh-cn
name
Antibodies to normal human melanocytes in vitiligo.
@en
Antibodies to normal human melanocytes in vitiligo.
@nl
type
label
Antibodies to normal human melanocytes in vitiligo.
@en
Antibodies to normal human melanocytes in vitiligo.
@nl
prefLabel
Antibodies to normal human melanocytes in vitiligo.
@en
Antibodies to normal human melanocytes in vitiligo.
@nl
P2093
P2860
P356
P1476
Antibodies to normal human melanocytes in vitiligo.
@en
P2093
Bystryn JC
Eisinger M
Naughton GK
P2860
P304
P356
10.1084/JEM.158.1.246
P407
P577
1983-07-01T00:00:00Z